Fresenius Medical Care North America Partners with Livongo to Empower People with Chronic Kidney Disease
WALTHAM, Mass. and MOUNTAIN VIEW, Calif., Oct. 7, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, today announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD). The new partnership enables Fresenius Health Partners, a division of FMCNA, to better deliver targeted, real-time care coordination services through Livongo Whole Person for CKD.
Through Livongo Whole Person for CKD, people with CKD who are managed by Fresenius Health Partners under a contract with the health plan, will have access to Livongo's proven diabetes and hypertension management solutions. This marks the first time Livongo will use its robust virtual care solutions to specifically support those with CKD and is a significant step forward in Fresenius Medical Care's efforts to provide a more coordinated care experience. With earlier intervention, Fresenius Health Partners also seeks to increase optimal dialysis starts, as well as offer earlier evaluation of transplantation and home dialysis options.
"By adding Livongo to our value based care services, we can make a positive impact in the lives of people living with kidney disease," said Bill Valle, CEO of FMCNA. "We are excited to add this proven suite of technologies and services as we expand our leadership in renal care management and work to slow the progression of kidney disease."
Livongo makes it easier for members to manage their health by providing a connected ecosystem that includes cellular-connected devices and integration with continuous glucose monitors, access to health coaches, and real-time health insights delivered through Health Nudges. The Applied Health Signals platform leverages data science to understand people's unique health needs and then provide clinically-based guidance to drive positive behavior change. Livongo's different approach creates a better member experience1 that leads to clinical outcomes2 and cost savings3.
"Through Livongo's advanced data science engine and clinically-based approach, we can effectively use our proven solutions to empower individuals living with chronic kidney disease," said Glen Tullman, Livongo Founder and Executive Chairman. "We are excited about our innovative partnership with Fresenius Medical Care North America to offer people living with chronic kidney disease a better care experience that is personalized to them and addresses all aspects of their health."
These programs aim to improve health outcomes while reducing the health plan's financial risk for this challenging population.
About Fresenius Medical Care North America
About Fresenius Health Partners
Fresenius Medical Care North America
1 Data from 2019 S1.
2 Data from 2019 S1 for diabetes, hypertension, and depression. Weight management from data on file (DS-3S47).
3 Data from 2019 S1 for retention rate. Average Per Member Per Month medical saving and Average year 1 ROI from data on file (DS-3S47).
View original content to download multimedia:http://www.prnewswire.com/news-releases/fresenius-medical-care-north-america-partners-with-livongo-to-empower-people-with-chronic-kidney-disease-301148135.html
SOURCE Fresenius Medical Care Holdings, Inc.